Brian Collins wrote: >It seems to me that almost everyone is missing the point about this >non-event. I will try again to convey the points which are really >irritating me. > >1/ SmithKline Beecham have made NO major breakthrough. >2 SmithKline Beecham have simply re-stated what we have all known for the > past 5 years: that the Dopamine Agonists from Permax on are capable of > acting like dopamine to the nervous system, without increasing the > risk of dyskinesia. Brian, Just so you don't lose any sleep over this... I wasn't 'fooled.' When the report first came out, I commented to Al that this wasn't new, so what's the big deal? I suspect many of us who have been on the PD trail for a while also were not fooled. >3/ I admit to a grudging respect at SKB's nerve at wrapping the package > so that it fools (apparently) just about everyone at the conference. We don't know that anybody at the conference was fooled either. The reporters who covered the conference might have been impressed because they are probably not knowledgable about Parkinson drugs. I recently heard a local TV commentator say, "A press release is one opinion of a multi-sided issue." As always, we have to take everything we read with a grain of salt. Rest easy my friend... Judith -- Judith Richards, London, Ontario, Canada [log in to unmask] ^^^^ \ / \ | / Today’s Research \\ | // ...Tomorrow’s Cure \ | / \|/ `````